Published in Cancer Weekly, October 30th, 2001
Dyax will use its phage display technology to identify small proteins, peptides (protein fragments), and antibodies that bind to two serine protease targets isolated and characterized by Corvas. Corvas will apply its expertise in target validation and preclinical biology, including the expression and purification of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.